截至月份: 2025年10月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | 李氏大藥廠控股有限公司 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | | 本月底結存 | | | 1,000,000,000 HKD | | | 0.05 HKD | | | 50,000,0 ...

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) announced the grant of stock options to several qualified participants under the stock option plan adopted on May 19, 2022, with a total of 1.764 million shares available for subscription [1] Summary by Category - **Company Announcement** - The company will grant stock options on October 15, 2025, allowing the subscription of a total of 1.764 million ordinary shares [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950) announced the granting of stock options to several qualified participants under the stock option plan adopted on May 19, 2022, allowing the subscription of a total of 1.764 million ordinary shares of the company [1] Group 1 - The stock options were granted on October 15, 2025 [1] - The total number of shares that can be subscribed through the stock options is 1.764 million [1]

Core Viewpoint - Lee's Pharmaceutical Holdings Limited (00950.HK) announced the granting of stock options to several eligible participants under the stock option plan adopted on May 19, 2022, which allows for the subscription of a total of 1.764 million ordinary shares of the company [1] Group 1 - The stock options will be granted on October 15, 2025 [1] - The total number of shares available for subscription through the stock options is 1.764 million [1]

截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 李氏大藥廠控股有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00950 | 說明 | | 李氏大藥廠控股有限公司 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 0.05 | HKD | | 50,000,00 ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 950) N O T I F I C AT I O N L E T T E R 通 知 信 函 19 September 2025 Dear Non-registered holders, Lee's Pharmaceutical Holdings Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communication") The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the websi ...

Lee's Pharmaceutical Holdings Limited 李氏大藥廠控股有限公司 * (incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） (Stock Code 股份代號: 950) N O T I F I C AT I O N L E T T E R 通 知 信 函 Dear Registered Shareholders, Lee's Pharmaceutical Holdings Limited (the "Company") – Notice of Publication of Interim Report (the "Current Corporate Communication") The Current Corporate Communication of the Company have been published in English and Chinese languages and are available on the website of The Stock E ...

Financial Performance - The Group's revenue for the first half of 2025 was HK$694,821,000, reflecting a year-on-year growth of 5.5% from HK$658,345,000 in the same period of 2024[4] - Gross profit for the first half of 2025 was HK$360,053,000, an increase of 2.7% compared to HK$350,595,000 in the first half of 2024, despite a decrease in gross profit margin to 51.8%[6] - Net profit attributable to the owners of the Company for the first half of 2025 was HK$67,185,000, a 7.5% increase from HK$62,478,000 in the same period of 2024[14] - Profit for the period decreased to HK$50,546,000 from HK$54,869,000, reflecting a decline of 7.9% year-over-year[144] - Basic and diluted earnings per share increased to HK$11.41 from HK$10.61, marking a growth of 7.5%[144] - Total comprehensive income for the period was HK$288,956,000, compared to a loss of HK$327,563,000 in the previous year, showing a significant recovery[147] Expenses and Costs - R&D expenses increased by 88.6% to HK$159,756,000 in the first half of 2025, representing 23.0% of the corresponding revenue, up from 12.9% in the previous year[9] - Selling and distribution expenses decreased by 11.4% to HK$152,579,000, with the selling expenses to revenue ratio declining to 22.0%[10] - Administrative expenses totaled HK$101,600,000, representing a 4.7% increase compared to HK$97,054,000 in the same period of the previous year[13] - Other losses (net) amounted to HK$12,594,000 in the first half of 2025, compared to other gains (net) of HK$2,217,000 in the first half of 2024, primarily due to foreign exchange differences and asset write-offs[45] Product and Market Development - Licensed-in products contributed approximately 39.0% of the Group's revenue, while proprietary and generic products accounted for 61.0%[5] - The Group's strategic transition towards a more diversified product portfolio is reflected in the growth of lower margin generic products under national reimbursement schemes[6] - The Group's oncology pipeline includes 6 innovative assets and 4 generics, developed through internal R&D and licensing agreements, with a focus on immuno-oncology[23] - In July 2025, Socazolimab Injection received NMPA approval for a new indication in combination with chemotherapy for extensive-stage small-cell lung cancer, marking its second approved indication[28] - A total of 10 products are currently listed in the updated National Reimbursement Drug List (NRDL), reflecting the Group's commitment to expanding market access and improving patient affordability[38] Production and Capacity - The Hefei site introduced a new pre-filled production line, enhancing capacity for VBP products, including Fondaparinux Sodium Injection and Nadroparin Calcium Injection[16] - The Nansha site focused on scaling up production of Azilsartan Tablets and advanced validation batch production for Fentanyl aerosol inhalation[17] - The Group has significantly enhanced production capacity and efficiency at its manufacturing facilities, particularly at the Hefei base with a new automated pre-filling production line, improving the output of key products like Sulfadiazine Sodium Injection and Nadroparin Calcium Injection[19] Financial Position and Liquidity - The total balance of other payables and accruals as of June 30, 2025, was HK$547,210,000, an increase of HK$76,273,000 from HK$470,937,000 at the end of 2024[55] - The Group's current ratio improved to 1.07 as of June 30, 2025, compared to 1.02 at the end of 2024, indicating better liquidity[56] - The net cash position increased significantly to HK$73,338,000 as of June 30, 2025, from HK$2,980,000 at the end of 2024[58] - Cash and cash equivalents at June 30, 2025, totaled HK$303,576,000, up from HK$190,794,000 in 2024, indicating a growth of about 59%[158] Share Options and Compensation - The Company adopted the 2022 Share Option Scheme on May 19, 2022, following the expiration of the 2012 Share Option Scheme[71] - The exercise price for options granted to directors ranges from HK$5.754 to HK$11.216[74] - A total of 1,476,000 options were granted during the reporting period[75] - The company has a structured approach to stock option grants, ensuring alignment with performance[77] - The total number of options available for exercise as of June 30, 2025, is 1,476,000[75] Governance and Compliance - The company has complied with the Corporate Governance Code throughout the six months ended June 30, 2025[125] - No purchases, sales, or redemptions of listed securities occurred during the six months ended June 30, 2025[122] - The company has confirmed that all directors complied with the Model Code regarding securities transactions throughout the accounting period[119] Risk Management - The Group's activities expose it to various financial risks, including market risk, credit risk, and liquidity risk[173] - There have been no significant changes in the Group's risk management policies since the year-end[177] - Actual results may differ from estimates made in the preparation of the unaudited condensed consolidated financial statements[172]

Core Viewpoint - Lee's Pharmaceutical (00950) has shown significant stock price increase following the release of its interim results, indicating strong sales performance and growth in profit [1] Financial Performance - The company reported revenue of HKD 695 million, representing a year-on-year increase of 5.5% [1] - The profit attributable to shareholders for the first half of 2025 was HKD 67.185 million, reflecting a year-on-year growth of 7.5% [1] Product Development and Approvals - Lee's Pharmaceutical announced that its subsidiary, Zhaoke Pharmaceutical, received approval for the new indication of the anti-PD-L1 monoclonal antibody, Socazolimab [1] - The company is developing an aerosol inhalation fentanyl product, AZ003, which is aimed at effectively managing breakthrough cancer pain, with Phase II clinical results expected to be presented at ASCO 2024 [1] Industry Insights - According to Zhongtai Securities, recent advancements in dual antibodies, ADCs, small molecule targeted therapies (TKIs), and cell therapies are extending overall survival (OS) for cancer patients [1] - The focus on improving the quality of life (QoL) for cancer patients has become increasingly important, with fewer companies developing targeted medications for palliative care [1] - The report suggests that the market for palliative treatments addressing cancer cachexia and breakthrough pain is expected to see the emergence of several major products, highlighting investment opportunities [1]

Core Viewpoint - Lee's Pharmaceutical (00950) experienced a significant stock increase of over 27%, with a current rise of 20.9% to HKD 2.43, driven by positive mid-term performance results and product approvals [1] Financial Performance - The company reported a revenue of HKD 695 million, reflecting a year-on-year increase of 5.5% [1] - The net profit attributable to shareholders for the first half of 2025 was HKD 67.185 million, marking a 7.5% increase compared to the previous year [1] Product Development and Approvals - Lee's Pharmaceutical announced that its subsidiary, Zhaoke Pharmaceutical, received approval for the new indication application of the anti-PD-L1 monoclonal antibody, Socazolimab [1] - The company is developing an aerosol inhalation fentanyl product, AZ003, aimed at effectively managing cancer pain, with Phase II clinical results expected to be presented at ASCO 2024 [1] Market Insights - According to Zhongtai Securities, recent advancements in dual antibodies, ADCs, small molecule targeted therapies (TKIs), and cell therapies have progressively extended overall survival (OS) for cancer patients [1] - The focus on improving the quality of life (QoL) for cancer patients has become increasingly important, with fewer companies developing targeted therapies for issues like cancer cachexia and breakthrough cancer pain [1] - The report suggests that the oncology palliative care sector is gaining attention, and Lee's Pharmaceutical's developments in this area could lead to significant market opportunities [1]